Loss of heterozygosity on chromosomes 1 and 11 in carcinoma of the pancreas. by Ding, S. F. et al.
Br. J. Cancer (1992), 65, 809 812 © Macmillan Press Ltd., 1992
Loss of heterozygosity on chromosomes 1 and 11 in carcinoma of the
pancreas
S.-F. Ding",2, N.A. Habib'2, J.D.A. Delhanty3, L. Bowles3, L. Greco2, C. Wood2,
R.C.N. Williamson2 & J.S. Dooley4
University Departments of 'Surgery and 4Medicine, Royal Free Hospital School ofMedicine, Pond Street, London NW3 2QG;
2Department ofSurgery, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London W12 ONN;
3Department ofGenetics and Biometry, University College London, 4 Stephenson Way, London NWJ 2HE, UK.
Summary Little is known of the molecular-genetic changes in carcinoma of the pancreas (CaP). In order to
investigate the allele loss, or loss of heterozygosity (LOH), in CaP, we studied 13 patients with exocrine CaP
and two with endocrine CaP using restriction fragment length polymorphism analysis. Twenty probes assigned
to chromosomes 1, 5, 7, 9, 11, 12, 13, 14, 16, 17 and 18 were used. The frequency of LOH, or fractional allele
loss (FAL), was found in two endocrine tumours to be 0.333 and 0.455 respectively; and FAL in 13 oxocrine
tumours ranged from 0 to 0.25. Allele loss was shown in both exocrine and endocrine tumours by the probes
Lambda MS1 at lp33-35, and pMS51 at llql3. Probes for other chromosomes have as yet shown no
consistent LOH. In conclusion, the study showed LOH on chromosomes 1 and 11 in both exocrine and
endocrine CaP.
Carcinoma of the pancreas (CaP) is an increasingly common
disease. The prognosis of CaP is poor with an overall mean
survival of 3-4 months; only about 5% of patients survive
for 2 years. Few tumours are amenable to resection with the
chance of 'cure'. Neither radiotherapy nor cytotoxic drugs
improve the prognosis significantly.
Much evidence has accumulated that loss of tumour sup-
pressor genes is important in carcinogenesis (Stanbridge,
1990). A variety of tumours, including both inherited child-
hood and common adult malignancies, exhibit allele loss, or
loss of heterozygosity (LOH), revealed by DNA restriction
fragment length polymorphism (RFLP) analysis (Sager,
1989). Consistent loss of heterozygosity may represent
tumour suppressor gene loss. Several such genes have been
cloned, such as RB 1 (retinoblastoma) (Friend et al., 1986;
Lee et al., 1987), DCC (deleted in colorectal cancer) (Fearon
et al., 1990), MCC (mutated in colorectal cancer) (Kinzler et
al., 1991a) and most recently, APC (adenomatous polyposis
coli) (Kinzler et al., 1991b; Groden et al., 1991).
There are few reports about allele loss in CaP, in contrast
to the comprehensive studies of other common malignancies,
such as those in breast (Devillee et al., 1989), colorectum
(Vogelstein et al., 1989), liver (Fujimori et al., 1991) and lung
(Kok et al., 1987). Allele losses on chromosome 11 in both
sporadic and familial pancreatic endocrine tumours, related
to multiple endocrine neoplasia type 1 (MEN 1), have been
reported (Bale et al., 1991; Teh et al., 1990). There have been
preliminary reports of allele loss on 5q for exocrine CaP
(Michelassi et al., 1989; Westbrook et al., 1990). It is of
interest to know whether allele loss on chromosome 11 or
other chromosomes also occurs in exocrine CaP, and whether
there is any association between allele loss and clinical course
in patients with CaP. Here we report a study of allele loss in
CaP by screening with 20 RFLP markers, and the relation-
ship between fractional allele loss and clinical parameters.
Materials and methods
Patients and biopsies
Fifteen patients with carcinoma of the pancreas were studied,
including two with endocrine CaP and 13 with exocrine CaP.
Of the 13 with exocrine CaP 12 had tumours of the head of
pancreas while the remaining one had a tumour of the
ampulla of vater. All underwent resection of their tumours
(either by partial or total pancreatectomy) except one patient
with peritoneal secondaries that had palliative bypass
(hepaticojejunostomy and gastrojejunostomy). Of the 13
patients with exocrine CaP, four had their tumours localised
to the pancreas while the other nine had metastases in local
lymph nodes or extension of their tumours in adjacent portal
vein. Judged by the operating surgeons, seven patients had
small tumours that were resected radically while the remain-
ing six had large tumours or late diseases such that their
surgical procedures should be considered palliative. All
patients, if applicable, were followed-up for detection of
post-operation recurrence. The data were available until 1
year after tumour resection.
Surgical biopsies from the tumoral and non-tumoral pan-
creas tissues were snap frozen in liquid nitrogen at the time
of operation. Lymphocytes from peripheral blood obtained
pre-operatively were also used as a source of normal DNA.
Tissue was stored at - 70'C until DNA extraction. None of
the patients received chemotherapy or radiotherapy prior to
surgery and tumour samples were examined histologically to
confirm the type of tumour present and the degree of
differentiation of tumour cells.
DNA extraction and analysis
DNA was prepared from blood and tissue samples by stan-
dard methods (Sambrook et al., 1989). Southern analyses
were done as previously described (Ding et al., 1991). The
20 RFLP probes for chromosomes 1, 5, 7, 9, 11, 12, 13, 14,
16, 17 and 18 and the appropriate restriction enzymes are
listed in Table I. If two alleles appeared as two separate
bands in the resultant autoradiograph of the constitutional
DNA, the patient was considered 'informative', or heterozy-
gous, for the particular marker. Complete deletion or great
loss of intensity of one band in the tumour DNA indicated
an allele loss, or an LOH. The fractional allele loss (FAL)
was defined in a tumour as the number of chromosomal arms
on which allelic loss was observed divided by the number of
chromosomal arms for which allelic markers were infor-
mative in the patient's normal cells (Vogelstein et al., 1989).
Statistical analysis
The significance of the relationship between frequency of
allele loss and clinical parameters was checked by the
Fisher's exact test (Bland, 1987).
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Chromosomal Enzyme Exocrine Endocrine
Probe region used CaP (n = 13J CaP (n =2)
AMSIa lp33-35 Hinfl 3/12b 2/2
AXMS32 lq42-43 Alul 0/11 2/2
cMS621 Sp Hinfl 0/5 0/2
ECB27 Sq21 Bglll 0/4 0/1
YN5.48 5q2l-22 MspI 0/4 1/1
lXMS8 5q35-qter Hinfl 0/10 0/1
AMS31 7pter-q22 Hinfl 0/8 0/2
pAkg3 7q3l.3-qter Hinfl 0/5 1/2
EFD126.3 9q34 PvuII 1/11 0/2
H-ras 1lplS BamHI 0/3 2/2
pMS51 Ilql3 Haelll 2/7 1/1
lMS43 12q24.3-qter Hinfl 0/11 0/2
P3.8R 13ql14.2 Hindlll 0/8 0/2
cMS626 13q Hinfl 0/5 0/2
cMS627 14q Alul 0/5 0/1
3'HVR 16pl13.3 PvuII 0/10 1/1
pulB1148 16q22.1 TaqI 0/0 0/0
p144-1D6 17pl3 RsaI 0/9 0/2
pYNZ22 17pl3 Rsal 0/6 0/2
cMS440 18q Haelll 0/5 0/1
'References for probes: AMSI1, lMS32, AMS8, AMS31, pAg3 and AMS43:
Wong et al., 1987; cMS621, cMS626, cMS627 and cMS440: Armour et al., 1990;
ECB27: Varesco et al., 1989; YN5.48: Nakamura et al., 1988a; EFD126.3:
Nakamura et al., 1987; H-ras: Krontiris et al., 1985; pMS51: Armour et al.,
1989; P3.8R: Friend et al., 1986; 3'HVR: Higgs et al., 1986; pulB1I148: vd
Straten et al., 1983; p144-1D6: Kondoleon et al., 1987; pYNZ22: Nakamura et
al., 1988b. bNo. with allele loss/No. of informative cases.
Table II Allele loss in individual tumours
Patient Chromosomal arms
name and on which allelic
age (year) markers were lost Arms with no allele loss FAL
Endocrine CaP (n = 2)
JJ (32) lp, lq, Ilp, llq, 16q 5p, 5q, 7p, 7q, 9q, 12q, 13q, 14q, 17p, 18q 5/15 (0.333)
HA (47) lp,'Ilq, 5q, 7q, Illp 5p, 7p, 9q, 12q, 13q, 17p 5/11 (0.455)
Exocrine CaP (n = 13)
CJ (48) 9q lp, lq, 5p, 7p, 7q, 12q, 13q, 14q, 16p, 17p, 18q 1/12 (0.083)
LA (49) lp, lq, 5p, 5q, 7p, 7q, 9q, Illp, 13q, 14q, 16p, 17p 0/12 (0.000)
BA (68) lp Ilq, 5p, 5q, 7p, 9q, Illp, 13q, 16p, 17p, 18q 1/11 (0.091)
BE (52) llq lp, lq, 5p, 5q, 7p, 7q, 9q, 12q, 13q, 14q, 16p, 17p, 18q 1/13 (0.077)
SD (55) lq, 5p, 5q, 7p, 7q, llp, llq, 13q, 16p, 17p 0/11 (0.000)
KE (50) lp, lq, 5q, 7q, Illq, 12q, 13q, 16p 0/8 (0.000)
PD (60) lp, lq, 5q, 7p, 9q, 13q, 16p, 17p, 18q0/ (.0)
GP (61) ~~~~~~~~lp, lq, 5q, 7p, 9q, Illq, 13q, 16p, 17p, 18q 0/10 (0.000)
CV (51) lp lq, 5q, 7p, 9q, 13q, 16p, 17p 1/8 (0.125)
NW(67) lp, lq, 5q, Illq, 16p, 17p0/ (.0)
MF (33) llq lp, lq, 5q, 9q, 12q, 17p 0/7 (0.167)
PF (56) lp lq, 5q, 12q, 17p 1/6 (0.250)
KW(67) lp, 9q, Illq, 12q, 17p 1/4 (0.250)
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Results
Table I shows the overall allele loss in both exocrine and
endocrine CaP; and the results of allele loss obtained in each
tumour are shown in Table II. Overall, 171/252 Southern
blots were informative (heterozygosity: 67.9%) and the
overall LOH was 16/171 informative cases (9.4%). Figure I
shows representative examples of allele loss.
Both tumours from the two patients with endocrine CaP
had multiple allelic losses, with deletions on five
chromosomal arms each (Tables I and II). The FAL was
0.333 and 0.455 for the two tumours respectively. The com-
mon regions deleted were at lp33-35 (probe: Lambda MSI),
lq42-43 (Lambda MS32) and llplS (H-ras). One of the two
patients (patient JJ) had allele loss at Illql13 (probe: pMS51),
where the MEN I gene maps (Larsson et al., 1988), while the
other (HA) was non-informative for that marker. Patient HA
showed LOH at 5q2l-22, in the region of the adenomatous
polyposis coli (APC) gene, but both of the two probes used
for this region (ECB27 and YN5.48) showed a homozygous
pattern for patient JJ and were hence uninformative.
As shown in Tables I and II, the 13 exocrine CaP had
LOH in three out of 12 informative cases (25%) at the region
lp33-35, one of 11 (9%) at 9q34 and two of seven (28.6%) at
IIlql13, hecne both exocrine and endocrine tumours exhibited
LOH at lp32-33 and I IqI3, the latter ofwhich is close to the
MEN I gene. The probe P3.8R for the RBI gene at 13ql4.2
showed no allele loss, nor did another probe, cMS626,
screening 13q in either exocrine and endocrine tumours. For
both groups, there was no allele loss found at 17pl3 (where
the pS3 tumour suppressor gene maps), shown by the two
probes used (pI44-D6 and pYNZ22). The FAL in exocrine
tumours ranged from 0 to 0.25 (Table II).
The possible relationship between allele loss and some
clinical parameters in exocrine CaP was analysed (Table III).
Of seven small tumours (<3cm), one had an allele loss,
while out of six large tumours (>3 cm) five showed LOH
(P <0.05). Allele loss was shown in four out of five tumoursLOH IN CAP 811
JJ informative patient with endocrine CaP in our study also had






Figure 1 Representative autoradiographs of
tion with Lambda MS1 (lp33-35), Lambda r
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aSize: < 3 cm = small, > 3 cm = large. bb
cMetastasis: regional lymph nodes or liver de
patients died from operative complication an
had very short follow-up.
from patients with recurrence, while
tumours from the patients without recurr
(P <0.05). There was a trend that tui
differentiation or with metastasis had mo
the differences were not statistically sign
allelee ious ill Llis reguio. illtlestillnlgy, LInere was i.'ixi snUWn
by the marker at this region in two of seven informative
cases of exocrine CaP, which has not been reported before.
Whether the change in this region is involved in the develop-
ment of exocrine CaP needs further study.
There are relatively few cytogenetic studies on CaP, but
one study of particular interest showed deletion on
B T cnromosome lpi2 in one tumour ana a translocauon involv-
ing that breakpoint in a second (Johansson et al., 1991). XMS 1 Allele loss at lp33-35 was shown by the probe Lambda MSI
ii in this study in both exocrine (three out of 12 informative
rcacle TAih1 T) and Pneocrine ()2/) Tahle i) CaP which mav
indicate a possible tumour suppressor gene located there for
both types ofCaP, but as this region is frequently involved in
advanced cancers of other types, its loss may be related to
tumour progression (reviewed in Sager, 1989). More cases are
needed to confirm the preliminary finding. It is of interest
that allele loss also occurred on chromosome lq in both
endocrine cases, which may suggest that loss of genetic
material in this region may be of importance for endocrine
tumours.
Recently, loss or mutation of the p53 tumour suppressor
B T gene at 17p13 has been seen at very high frequency in several
pMS 51 common human malignancies (Stanbridge, 1990). A recent
study in exocrine CaP also showed high frequency of over-
Southern hybridisa- expression of mutant forms of p53 by immunohistochemistry
MS 32 (Iq42-43) and and of point mutations of the p53 gene by direct sequencing
A, N = Non-tumour of genomic DNA (Barton et al., 1991). Hence it was surpris-
Ul show allelic losses ing to find that there was no allele loss shown by either
iaP while Patient JJ probe (pl44-D6 or pYNZ22) at 17p13 in either group of CaP
in our study. This was in agreement with the finding of
Westbrook et al. (1990), who did not find any LOH with
pYNZ22 in seven informative pancreatic adenocarcinomas. It
will be of interest to know if there is any overexpression of
iicreas mutant p53 or point mutation of the p53 gene in our two
groups of CaP.
ele loss Significance Frequent rearrangement or loss of the prototype tumour
suppressor gene, retinoblastoma (RB), also occurs in some
p<o.05 other types of tumours (Horowitz et al., 1990). No allele loss
was shown by one of the cDNA probes from the RB gene in
the two groups of CaP in this study.
Westbrook et al. (1990) reported allele loss in two out of
N.S.b seven informative exocrine CaP on chromosome 5 and sug-
gested that the genetic changes associated with allele loss on
that chromosome might be a common denominator in the
development or progression of the gastrointestine cancers
N.S. including those ofcolorectum and pancreas. In our study, the
one informative endocrine CaP showed allele loss at 5q21-22,
but four probes on chromosome 5 did not reveal LOH in the
P <0.05 exocrine CaP group. Vogelstein et al. (1989) reported that for colorectal car-
cinomas, patients with more LOH had a considerably worse
4.S.: Not significant. prognosis than did the other patients. In this study we
posits. dTwo of these analysed the possible correlation between frequency of loss of
id the remaining two heterozygosity and some clinical parameters within the group
of exocrine CaP (Table III). There was a significant correla-
tion found between the frequency of allele loss and the
tumour size, and presence or absence of recurrence. The
other data in Table III also showed a trend toward more
none of the four aggressive behaviour in tumours with LOH. However it
rence had allele loss failed to reach statistical significance. A large study should be
mours with poorer conducted in order to confirm the significance of these data.
tre allelic losses, but In conclusion, the study showed LOH on chromosomes
lificant (Table III). lp33-35 and llql3 in both exocrine and endocrine CaP. In
the group of exocrine CaP, patients with larger tumours, or
recurrence may have more allelic losses in their tumours.
Discussion
This study showed loss of heterozygosity on chromosomes
lp33-35 and 1 lql3 in both exocrine and endocrine car-
cinomas of the pancreas. Allele loss at 11 ql3 has been
revealed in both sporadic and familial tumours arising in the
endocrine pancreas (Bale et al., 1991; Teh et al., 1990). The
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